Skip to content

Discontinued — last reported Q1 '26

EBIT at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$30.9M+42.5%
PTH
Pelthos Therapeutics Inc.PTHS
-$13.09M-614%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.89M-7.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$52.15M+1,073%
Opko Health logo
Opko HealthOPK
-$51.02M+24.0%
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$8.6M+72.1%
Gross profit$4.2M+15.1%
Operating income-$32.2M-15.3%
Net income-$45.7M-75.0%
EPS (diluted)-$6.28-178%

Balance sheet

See full
Cash & equivalents$3.4M-42.2%
Total debt$95.4M+130%
Total equity-$249.2M-17.8%
Total assets$293.6M+272%

Cash flow

See full
Operating cash flow-$1.1M-118%
CapEx$33.3K
Free cash flow$920.8K-63.7%

Valuation

See full
Market cap$54.86M+88.7%
Enterprise value$146.86M+120%
P/S1.6×+1.0×

Profitability

See full
Gross margin59.7%-12.3pp
Operating margin-1,034.4%-1,313pp
Net margin-1,162.4%-1,359pp
FCF margin12.2%

Returns & leverage

See full
Return on equity170.9%
Debt / equity0.3×
Current ratio0.1×0.0×

Where this comes from

Calculated from Scilex Holding Company’s reported figures.

The official record: Scilex Holding Company’s 10-Q, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scilex Holding Company's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scilex Holding Company's EBIT?
Scilex Holding Company (SCLX) reported EBIT of -$32.17M in Q1 2026.
How has Scilex Holding Company's EBIT changed year-over-year?
Scilex Holding Company's EBIT decreased by 15.3% year-over-year, from -$27.9M to -$32.17M.
What is the long-term trend for Scilex Holding Company's EBIT?
Over 4 years (2021 to 2025), Scilex Holding Company's EBIT has grown at a 76.3% compound annual growth rate (CAGR), from -$35.84M to -$346.01M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.